A detailed history of Amalgamated Bank transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 16,019 shares of RCUS stock, worth $254,862. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,019
Previous 16,184 1.02%
Holding current value
$254,862
Previous $246,000 0.41%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$13.69 - $18.01 $2,258 - $2,971
-165 Reduced 1.02%
16,019 $245,000
Q2 2024

Aug 12, 2024

SELL
$14.59 - $18.48 $16,880 - $21,381
-1,157 Reduced 6.67%
16,184 $246,000
Q1 2024

Apr 23, 2024

SELL
$14.83 - $20.18 $54,663 - $74,383
-3,686 Reduced 17.53%
17,341 $327,000
Q4 2023

Feb 06, 2024

SELL
$13.43 - $19.63 $12,933 - $18,903
-963 Reduced 4.38%
21,027 $402,000
Q2 2023

Aug 11, 2023

BUY
$16.97 - $22.03 $4,615 - $5,992
272 Added 1.25%
21,990 $446,000
Q1 2023

May 02, 2023

SELL
$15.96 - $23.15 $29,940 - $43,429
-1,876 Reduced 7.95%
21,718 $396,000
Q4 2022

Feb 10, 2023

BUY
$19.7 - $35.71 $3,092 - $5,606
157 Added 0.67%
23,594 $488,000
Q3 2022

Nov 09, 2022

BUY
$23.23 - $30.07 $43,695 - $56,561
1,881 Added 8.73%
23,437 $613,000
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $278,212 - $609,226
16,147 Added 298.52%
21,556 $546,000
Q1 2022

Jun 30, 2022

SELL
$28.92 - $41.83 $12,406 - $17,945
-429 Reduced 7.35%
5,409 $171,000
Q4 2021

Feb 15, 2022

SELL
$31.38 - $48.47 $2,730 - $4,216
-87 Reduced 1.47%
5,838 $236,000
Q3 2021

Oct 29, 2021

BUY
$26.93 - $37.68 $159,560 - $223,254
5,925 New
5,925 $207,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.15B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.